The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 5.20
Ask: 5.30
Change: 0.00 (0.00%)
Spread: 0.10 (1.923%)
Open: 5.20
High: 5.30
Low: 5.20
Prev. Close: 5.25
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Sabien works with Empiric; Coro sells in Italy

Mon, 27th Mar 2023 18:42

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Sabien Technology Group PLC - technology company, focused on the heating, cooling and transportation sectors - Completes work with Empiric Student Property PLC to help the student accommodation provider's goals to become net zero by 2033. "Sabien's M2G business, Sabien Technology Ltd, which focuses on CO2 mitigation devices for commercial boilers, has been working with its mutual partner, Amber Energy Solutions Ltd, over the last six months to install equipment across eight properties in Empiric's portfolio to reduce CO2 emissions," Sabien says "Empiric Student Property has also adopted Sabien's M2G cloud connect solution to support the delivery of energy efficiencies and cost savings across these properties, as well as the monitoring of longer-term energy use with the potential for further system optimisation opportunities."

----------

Coro Energy PLC - South East Asia-focused energy - Signs deal for disposal of Italian assets to Zodiac Energy PLC for up to EUR7.5 million. Initial cash payment of EUR1.5 million to be made to Coro within seven working days. Proposed disposal needs shareholder approval at general meeting scheduled for April 25. Coro says: "The company remains primarily focused on Southeast Asia and the significant growth and investment opportunities the region provides. In expectation of near term and long awaited developments on the Duyung PSC and the company's renewable portfolio in Southeast Asia and with a view to capturing the value inherent in the Italian Portfolio following gas price rises, the [sale purchase agreement] was concluded with Zodiac, with the consideration then being available to deploy in line with the stated strategy.

----------

Anglo Asian Mining PLC - Azerbaijan-focused gold, copper and silver producer - Lauds data at Garadag deposit. Findings confirm potential of asset to produce over 300,000 tonnes of copper. Anglo Asian adds: "This initial assessment by the company has not been prepared according to the JORC standard. The company intends to prepare a mineral resource estimate using the JORC procedures on completion of the evaluation programme, targeting mid-2024 for the preparation of the mineral resource estimate according to the JORC code."

----------

Global Petroleum Ltd - oil & gas exploration in Africa and the Mediterranean - Reports updated prospective resources estimate for PEL0094 licence in offshore Namibia. Company has 78% working interest in asset and serves as operator. Reports unrisked gross prospective resources of 3.5 million barrels of oil at asset, up from 3.3 million previously. "As the initial conclusion from our further technical work, we are pleased to report the very significant increase in prospective resources - as well as the improved risking - for our primary prospect, Marula. This, together with the supporting technical detail, will now be communicated to potential farm-in partners," company adds.

----------

Clean Power Hydrogen PLC - Doncaster, England-based green hydrogen technology and manufacturing company - New Zealand-based partner Fabrum Solutions Ltd receives order an order from construction firm Obayashi Corp for delivery of MFE220 unit. "The order represents Fabrum's first customer under CPH2's manufacturing agreement for which CPH2 will receive a technology fee as well as revenue from the sale of key components including CPH2 stacks," Clean Power says.

----------

AEW UK REIT PLC - real estate investment trust for UK regional commercial property - Acquires freehold retail warehousing unit in Bamber Bridge, Preston for GBP6.5 million. Asset is single-let to retailer Matalan Retail Ltd with over nine year left on lease. "Matalan is known to trade strongly from the location, with the store being one of its top 10 performers, as well as being the retailer's first ever store in the U.K. The lease benefits from a 2027 rent review to the higher of open market value, or 2.5% per annum compounded, resulting in a minimum reversionary yield of 10.7%," AEW UK REIT says.

----------

Jade Road Investments Ltd - Hong Kong-based investment firm - Says manager Harmony Capital Investors Ltd will advise firm on orderly disposal of investments it currently owns, a batch of assets it labels as "legacy portfolio". "HCIL shall, subject to the overall supervision and control of the board, also undertake general administrative, investor relations, marketing, portfolio management and risk management functions for the company," Jade Road says. Instead of an annual management fee, HCIL is to now be paid a fixed fee of USD350,000 for services connected to disposals. Jade Road adds: "This represents a substantial reduction in fees as compared to the previous agreement." Executive Chair John Croft says: "In line with the recent change to our investment policy and refocus of the company, we remain committed to the orderly disposal of our legacy portfolio. The revised services agreement with HCIL has been negotiated to provide a better alignment with the company's current objectives. This agreement reflects the importance that the board places on achieving exits from its China and other Asia based investments so that surplus cash can be deployed into its revised investment strategy."

----------

Allergy Therapeutics PLC - biotechnology company focused on the treatment and diagnosis of allergic disorders - Patients dosed in phase 1 of Protect trial probing novel peanut allergy vaccine candidate VLP Peanut.

----------

Tristel PLC - Cambridgeshire-based maker of infection prevention, contamination control and hygiene products - Submits additional data requested by the US Food & Drug Administration ahead of decision on Duo ULT high-level disinfectant. Decision is expected before end of second quarter of 2023. Tristel says: "The FDA will now commence its final review of the De Novo submission and the agency's internal rules require it to make its decision by the company's financial year-end. The FDA approval will enable Duo's use for high-level disinfection of intra-cavity ultrasound probes. Duo is already approved by the US Environmental Protection Agency for use on skin-surface ultrasound transducers."

----------

Nuformix PLC - London-based pharmaceutical development company - Says data finds NXP002, designed to treat lung-scarring condition idiopathic pulmonary fibrosis, is "well tolerated in ex-vivo human lung tissue". Ex-vivo refers to outside of the body. "NXP002 alone delivers a strong, consistent anti-fibrotic effect as demonstrated by modulation of the release of multiple biomarkers of fibrosis," company adds. "Overall, the results provide further support of NXP002's potential to increase efficacy of existing therapies with the benefits of inhaled delivery."

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
3 Aug 2021 14:33

IN BRIEF: Allergy Therapeutics study confirms peanut vaccine potential

IN BRIEF: Allergy Therapeutics study confirms peanut vaccine potential

Read more
3 Aug 2021 13:43

Allergy Therapeutics upbeat on ex-vivo study of peanut allergy vaccine

(Sharecast News) - Pharmaceutical biotechnology company Allergy Therapeutics announced positive primary results from an ex-vivo biomarker study on Tuesday, evaluating its novel virus-like particle (VLP)-based peanut allergy vaccine candidate, VLP Peanut.

Read more
14 Jul 2021 12:29

Allergy Therapeutics expects revenue rise in year despite challenges

Allergy Therapeutics expects revenue rise in year despite challenges

Read more
24 Jun 2021 19:56

TRADING UPDATES: Vitec and Allergy Therapeutics lift full-year outlook

TRADING UPDATES: Vitec and Allergy Therapeutics lift full-year outlook

Read more
24 Jun 2021 08:07

Allergy Therapeutics FY profits seen 'well ahead' of expectations

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics said on Thursday that full-year operating profits were expected to be "well ahead" of market expectations thanks to "significantly lower" expenses.

Read more
6 May 2021 19:25

TRADING UPDATES: Superdry optimistic; Virgin Wines toasts demand surge

TRADING UPDATES: Superdry optimistic; Virgin Wines toasts demand surge

Read more
6 May 2021 15:34

Allergy Therapeutics completes treatment in G309 field study

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics announced the completion of the treatment of all patients in its 'G309' exploratory field study to evaluate the efficacy and safety of Grass MATA MPL in subjects with seasonal allergic rhinitis or rhinoconjunctivitis, induced by grass pollen.

Read more
3 Mar 2021 19:14

TRADING UPDATES: Capita sells Irish unit; Daily Mail buys science mag

TRADING UPDATES: Capita sells Irish unit; Daily Mail buys science mag

Read more
3 Mar 2021 13:23

Allergy Therapeutics reports record pre-R&D operating profit

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics reported a 7% improvement in its revenue in actual terms in its interim results on Wednesday, and 5% growth at constant rate, to £54.0m.

Read more
13 Jan 2021 13:29

IN BRIEF: Allergy Therapeutics Hails Growth; Non-Exec Smith To Leave

IN BRIEF: Allergy Therapeutics Hails Growth; Non-Exec Smith To Leave

Read more
5 Jan 2021 18:01

IN BRIEF: Allergy Therapeutics And Imperial Start Peanut Allergy Study

IN BRIEF: Allergy Therapeutics And Imperial Start Peanut Allergy Study

Read more
5 Jan 2021 16:44

Allergy Therapeutics begins peanut allergy vaccine study

(Sharecast News) - Speciality allergy-focussed pharmaceutical company Allergy Therapeutics announced on Tuesday that an ex-vivo biomarker study of blood samples from peanut allergy patients had started at Imperial College London.

Read more
8 Dec 2020 21:07

IN BRIEF: Allergy Therapeutics Shareholders Revolt At General Meeting

IN BRIEF: Allergy Therapeutics Shareholders Revolt At General Meeting

Read more
1 Dec 2020 16:06

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
20 Nov 2020 14:51

UK DIRECTOR DEALINGS SUMMARY: Landsec CEO Buys GBP300,000 Worth

UK DIRECTOR DEALINGS SUMMARY: Landsec CEO Buys GBP300,000 Worth

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.